Avalyn Pharma Inc. Common Stock (AVLN) vs Replimune Group, Inc. (REPL)

A side-by-side comparison of Avalyn Pharma Inc. Common Stock and Replimune Group, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Avalyn Pharma Inc. Common Stock logo
AVLN
Avalyn Pharma Inc. Common Stock
$1.13B
$25.45HealthcareDelayed quote: Oct 6, 2026, 1:54 PM EDT
Replimune Group, Inc. logo
REPL
Replimune Group, Inc.
$1.11B
$13.24HealthcareDelayed quote: Oct 6, 2026, 1:55 PM EDT

Total return — AVLN vs REPL

growth of $100 · dividends reinvested · last 1y
AVLN -8.3% (-8.3%/yr)REPL +452.5% (+452.5%/yr)REPL compounded faster over this window
Log scale — wide-divergence pair
101001kStart $100$92$553
AVLN REPL

AVLN vs REPL: by the numbers

  • •AVLN is the larger company ($1.13B vs $1.11B market cap).

Metrics side by side

Valuation

MetricAVLNREPL
P/B ratio2.8310.53

Profitability

MetricAVLNREPL
Gross margin0.00%0.00%
Operating margin0.00%0.00%
Net margin0.00%0.00%
ROEN/A-281.14%
ROIC-67.73%-139.11%

Growth (annualized)

MetricAVLNREPL
Total return CAGR (5Y)N/A-15.17%

Go deeper

Full AVLN analysisFull REPL analysisInteractive comparison tool

Dig into the metrics

Avalyn Pharma Inc. Common Stock ROEReplimune ROEAvalyn Pharma Inc. Common Stock operating marginReplimune operating marginAvalyn Pharma Inc. Common Stock revenue growthReplimune revenue growthAvalyn Pharma Inc. Common Stock free cash flowReplimune free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.